Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Thrombocytopenia" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-14 z 14
    Tytuł:
    A study of etiological spectrum in 106 cases of pancytopenia
    Autorzy:
    Singhal, Parul
    Mittal, Adreena
    Dixit, Ritvija
    Powiązania:
    https://bibliotekanauki.pl/articles/40570864.pdf
    Data publikacji:
    2024-06-30
    Wydawca:
    Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
    Tematy:
    anemia
    aplastic
    leucopenia
    megaloblastic
    pancytopenia
    thrombocytopenia
    Opis:
    Introduction and aim. Pancytopenia is the simultaneous presence of anemia, leucopenia and thrombocytopenia. The aim of this work was to study the etiological spectrum of pancytopenia in the National capital region of India, and evaluate the relationship of pancytopenia with serum vitamin B12 levels. Material and methods. This study is of a prospective and analytical type conducted on patients attending the outpatient and inpatient department of Santosh Medical College and the Saraswathi Institute of Medical Sciences tertiary care centers in NCR. Complete blood counts and peripheral blood smear examination was used for morphological classification and typing of anemia. Bone marrow aspiration and vitamin B12 estimation was performed where required. Results. The maximum number of pancytopenia cases were etiologically attributed to megaloblastic anemia (64.2%) followed by aplastic anemia (19.8%). Malaria was attributed to 6.6% cases of pancytopenia. Iron deficiency anemia and tuberculosis both accounted for 1.9% of cases. each. A history of drug intake and mixed nutritional anemia each contributed to 2.8% of cases. Serum vitamin B12 levels showed a significant relationship with pancytopenic cases. Conclusion. In our study, the main cause of pancytopenia is megaloblastic anemia which responds very well to treatment if diagnosed correctly in time. A detailed hematological assessment along with vitamin B12 levels should be evaluated in all cases of pancytopenia irrespective of the etiological categorization.
    Źródło:
    European Journal of Clinical and Experimental Medicine; 2024, 22, 2; 370-375
    2544-2406
    2544-1361
    Pojawia się w:
    European Journal of Clinical and Experimental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Drug-induced thrombocytopenia – etiology and alternative therapeutic approaches
    Autorzy:
    Rajashekaraiah, Vani
    Berikai Ananthakrishna, Anusha
    Powiązania:
    https://bibliotekanauki.pl/articles/29519508.pdf
    Data publikacji:
    2023-09-30
    Wydawca:
    Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
    Tematy:
    alternative therapeutics
    drug-induced thrombocytopenia
    phytochemicals
    platelets
    Opis:
    Introduction and aim. The cumulative incidence of drug-induced thrombocytopenia (DIT) is 10 cases per one million people per year with a prevalence of approximately 25% in critically ill patients. This review provides a comprehensive view of drug-induced thrombocytopenia, diagnosis, underlying mechanisms, common strategies in therapeutics, and potential alternatives. Material and methods. Databases such as “Google Scholar”, “PubMed”, “Medline” and “MDPI” was used for literature review with the keywords, “platelets”, “platelet disorders”, “thrombocytopenia”, “drug-induced”, “oxidative stress” “plant extracts”, “phytochemicals”, “antioxidants”, for the articles published between 2013-2023 and written in the English language. Analysis of the literature. Several antimicrobials, anti-cancer drugs, and antivirals are often reported to cause adverse effects during treatment, such as thrombocytopenia. A thorough understanding of the underlying pathophysiology is important for appropriate treatment. Even though an improvement in platelet count is observed after the discontinuation of the causative drug, there is a dire need for treatment in some cases due to associated complications. There are various pitfalls with conventional treatments which include clinical complications and lack of effectiveness. Conclusion. Interventions in therapeutics through antioxidants can aid in faster recovery. Various plant extracts and phytochemicals have been employed as therapeutics in platelet disorders due to their exceptional antioxidant activity. It is imperative to explore the bioactive components of natural products and their influence on platelet efficacy. Also, it highlights how antioxidants can be used as a safe, yet effective option as therapeutics for treating a complicated disorder such as DIT or be used as supplements to prevent adverse effects of existing treatments involving antibiotics and chemotherapeutics.
    Źródło:
    European Journal of Clinical and Experimental Medicine; 2023, 3; 617-626
    2544-2406
    2544-1361
    Pojawia się w:
    European Journal of Clinical and Experimental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Thrombocytopenia resistent to standard therapy in lupus patients – analysis of 3 cases and clinical statement
    Autorzy:
    Pawlak-Bus, K.
    Leszczynski, P.
    Kokot, M.
    Samborski, W.
    Powiązania:
    https://bibliotekanauki.pl/articles/2081605.pdf
    Data publikacji:
    2018
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    thrombocytopenia
    systemic lupus erythematosus (SLE)
    immunosuppressive treatment
    Opis:
    Hematologic disorders, including thrombocytopenia, are a common symptom of systemic lupus – Systemic Lupus Erythematosus (SLE). An important diagnostic and therapeutic issue is the severe and recurrent thrombocytopenia resistant to standard treatment. It requires extensive diagnostics and a multi-directional view on its causes beyond the autoimmune process. Currently, there is no single treatment regimen for these disorders. Corticosteroids (CS) are the first-line drugs, but their chronic use is a big problem, they are not always successful and often generate a number of complications, especially in moderate to high doses. In the case of thrombocytopenia associated with the activity of SLE, immunosuppressive therapy is the gold standard and may result in long-term remission of symptoms and clinical stabilization. The major problem is thrombocytopenia resulting from other causes, such as infection or medications. This study discusses severe recurrent thrombocytopenia on the basis of three clinical cases, analyzing both the various causes of disorders, and providing ways of management and treatment. Special attention is paid to the correlation of thrombocytopenia with the clinical and immunological activity of SLE. It seems that severe and refractory thrombocytopenia may be a critical point and largely determine the management and treatment possibilities of SLE.
    Źródło:
    Annals of Agricultural and Environmental Medicine; 2018, 25, 2; 229-233
    1232-1966
    Pojawia się w:
    Annals of Agricultural and Environmental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Heparin-induced thrombocytopenia as a cause of prolonged low platelet count in a patient with thrombotic thrombocytopenic purpura treated with plasmapheresis
    Autorzy:
    Winiarska, Agata
    Kwella, Norbert
    Stompór, Tomasz
    Powiązania:
    https://bibliotekanauki.pl/articles/1038669.pdf
    Data publikacji:
    2017
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    heparin-induced thrombocytopenia
    plasma exchange
    thrombotic thrombocytopenic purpura
    Opis:
    Thrombotic thrombocytopenic purpura (TTP) is a rare disorder belonging to thrombotic microangiopathies (TMA) and is caused by functional deficiency of the ADAMTS-13 metalloproteinase. Plasma exchange (PE) remains the treatment of choice in this disease. Here, were describe the case of a patient who apparently recovered from TTP following multiple sessions of PE, but remained thrombocytopenic. Careful analysis revealed the development of heparin-induced thrombocytopenia (HIT) that precluded platelet count (PLT) normalization. Full normalization of PLT followed discontinuation of PE and low-molecular weight heparin.
    Źródło:
    Acta Biochimica Polonica; 2017, 64, 2; 375-376
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Eptifibatide induced acute thrombocytopenia. Case report of 80- years old man with acute coronary syndrome
    Autorzy:
    Kuźma, Ł.
    Pogorzelski, S.
    Wróblewski, D.
    Struniawski, K.
    Róg-Makal, M.
    Nowak, K.
    Matys, U.
    Gajewska-Bachórzewska, H.
    Dobrzycki, S.
    Powiązania:
    https://bibliotekanauki.pl/articles/1918779.pdf
    Data publikacji:
    2018
    Wydawca:
    Uniwersytet Medyczny w Białymstoku
    Tematy:
    Thrombocytopenia
    glycoprotein IIb/ IIIa inhibitors
    acute coronary syndrome
    Opis:
    Introduction: Glycoprotein (Gp) IIb/IIIa is a platelet receptor participating in platelet aggregation. According to ESC guidelines, glycoprotein IIb/IIIa inhibitors might be considered during percutaneous coronary interventions in patients with the acute coronary syndrome. Purpose: A case study of profound thrombocytopenia in 80-year-old man with the acute coronary syndrome. Case presentation: An 80-year-old, medicationnaive man with acute coronary syndrome was admitted to the Department of Invasive Cardiology. Due to the unsuccessful invasive strategy, an intracoronary bolus of Gp IIb/IIIa inhibitor – eptifibatide - was administered. During the following intravenous infusion, large subcutaneous hematomas were observed. Eptifibatide infusion was discontinued. Drop in platelet count to 1 thou/μL without significant anemia was registered. A control sample in sodium citrate showed similarly low platelet count - 2 thou/uL. Acetylsalicylic acid and clopidogrel were discontinued, steroids were introduced. Neither PLT nor FFP transfusion were necessary. Consecutive lab tests showed the gradual increase of PLT up to 35 thou/μL at discharge. A week later, the patient did not complain of any cardiovascular or bleeding symptoms; hematomas resented significant involution. Laboratory findings were normal. During follow-up visit 30 days after the discharge, the patient presented no cardiovascular symptoms. Conclusions: There are patients at risk of druginduced thrombocytopenia, especially those with impaired kidney function and the elderly. In such cases, decisions concerning anti-platelet and antithrombotic therapy should be taken cautiously. Because of its rare occurrence, every case of severe thrombocytopenia in ACS patients should be reported. Moreover, such patients should be followed-up to minimalize risk of similar adverse events in the future.
    Źródło:
    Progress in Health Sciences; 2018, 8(2); 234-238
    2083-1617
    Pojawia się w:
    Progress in Health Sciences
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Management of patient with immune thrombocytopenia with antiphospholipid syndrome and monoclonal gammopathy of undetermined significance
    Autorzy:
    Ryżewska, Wiktoria
    Zarzycka, Malwina
    Witkowski, Michał
    Witkowska, Magdalena
    Robak, Tadeusz
    Powiązania:
    https://bibliotekanauki.pl/articles/2047812.pdf
    Data publikacji:
    2021-11-08
    Wydawca:
    Medical Education
    Tematy:
    immune thrombocytopenia
    monoclonal gammopathy of undetermined significance
    antiphospholipid syndrome
    Opis:
    Immune thrombocytopenia with antiphospholipid syndrome and monoclonal gammopathy of undetermined significance poses therapeutic dilemmas – whether we should modify the immune thrombocytopenia treatment in antiphospholipid syndrome, what is the influence of monoclonal gammopathy of undetermined significance on the course of immune thrombocytopenia and whether we should and how to prevent the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
    Źródło:
    OncoReview; 2021, 11, 4; 106-111
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Bovine neonatal pancytopenia in calves in Poland
    Autorzy:
    Jaskowski, J.M.
    Polak, M.P.
    Marszalek, A.
    Nowak, K.
    Frackowiak, H.
    Olechnowicz, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/30613.pdf
    Data publikacji:
    2012
    Wydawca:
    Polska Akademia Nauk. Czytelnia Czasopism PAN
    Tematy:
    bovine neonatal pancytopenia
    calf
    symptom
    bleeding
    diathesis
    thrombocytopenia
    ecchymosis
    etiology
    Polska
    Opis:
    Bovine neonatal pancytopenia (BNP), a newly emerged syndrome of discussed etiology in calves, has been diagnosed since 2006. Here we describe first cases of BNP in Poland. Between September 2008 and April 2011, 62 cases of BNP were diagnosed in dairy calves. Bleeding skin lesions were mostly pronounced in summer and early autumn. Severe thrombocytopenia was observed in all sick animals. All calves came from herds vaccinated against BVDV infection with PregSure BVD vaccine (Pfizer). Substitution of colostrum from dams of BNP positive calves with colostrum from dams from herds free of BNP was the only effective measure to avoid new cases in affected herds.
    Źródło:
    Polish Journal of Veterinary Sciences; 2012, 15, 3
    1505-1773
    Pojawia się w:
    Polish Journal of Veterinary Sciences
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Virological response to treatment with peginterferon alfa-2a in adolescents with chronic hepatitis B
    Autorzy:
    Pawlowska, Małgorzata
    Halota, Waldemar
    Kozielewicz, Dorota
    Jendryczka, Ewa
    Powiązania:
    https://bibliotekanauki.pl/articles/1039657.pdf
    Data publikacji:
    2012
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    peginterferon alfa-2a
    thrombocytopenia
    hepatitis B virus
    chronic hepatitis B
    Opis:
    Background: There are few data on the efficacy and safety of pegylated interferon treatment in adolescents with chronic hepatitis B. Aim: We conducted a pilot study in 13 adolescents with chronic hepatitis B treated with peginterferon alfa-2a at 100 µg/m2 once weekly for 48 weeks. Methods: HBV DNA was assessed by qPCR method. Results: After four weeks of treatment six adolescents had undetectable HBV DNA (<12 IU/mL). Seven adolescents - including five HBV negatives at week 4 - had undetectable HBV DNA (<55 IU/mL) at week 24, and seven adolescents - including all HBV DNA negatives at week 4 - had undetectable HBV DNA at week 48 of treatment (<55 IU/mL). Five adolescents had undetectable HBV DNA (<55 IU/mL) after 24 weeks of follow-up (sustained viral response). HBeAg seroconversion was achieved in one patient. HBsAg loss was documented at the end of therapy in two of the six adolescents HBV DNA negative at week 4 of treatment. Three adolescents withdrew from the treatment (two because of adverse events, one because of withdrawal of parental consent). Leukopenia was reported in seven adolescents and three individuals experienced thrombocytopenia. Except for one patient who discontinued treatment due to leukopenia, no dose modifications for adverse events or laboratory abnormalities were required. Conclusion: This pilot study shows that 48 weeks of treatment with peginterferon alfa-2a can result in sustained HBV DNA suppression, HBeAg seroconversion and HBsAg loss in adolescents with CHB. Larger and longer trials are now required to better define the magnitude of the benefit in this group of patients.
    Źródło:
    Acta Biochimica Polonica; 2012, 59, 4; 587-591
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Is coagulopathy a common consequence of a Vipera berus bite? A retrospective single centre study
    Autorzy:
    Dylag-Trojanowska, K.E.
    Hodorowicz-Zaniewska, D.
    Zybaczyńska, J.
    Szczepanik, A.M.
    Powiązania:
    https://bibliotekanauki.pl/articles/2081944.pdf
    Data publikacji:
    2018
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    Polska
    thrombocytopenia
    coagulopathy
    venom
    antivenom
    envenomation
    Vipera berus bite
    snake
    snakebite
    Opis:
    Introduction. The Vipera berus (common viper) is the only species of venomous snake found in Poland. The aim of this study was to determine to what extent coagulopathy has occurred as a post-bite complication. Materials and method. The medical records of 138 adult patients in the Sucha Beskidzka hospital with the diagnosis of snake bite between 2001–2014 were retrospectively analyzed. Demographic, clinical and laboratory data were collected. Antivenom was given to all patients, except one, with snake bites, but laboratory test were taken prior to administration of antivenom. Obtained results were compared to those of the control group, composed of 176 adults hospitalized in the same period for an elective laparoscopic cholecystectomy. Results. The mean platelet count in the study group was 239.94×109/L (SD=56.56) and 248.77×109/L (SD=57.82) in the control group. In 98% of the study group and 100% of the control group the platelet value (PLT) fell within laboratory norms (130 to 420×109/L), 2 patients after snake bites had a PLT lower than normal, and thrombocytosis was not observed in either group. A reference range of 0.85–1.3 INR below normal was found in 2 patients in the study group and 15 from the control group, while values above the normal range were found in 8 patients (6.7%) from the snake bite group and no patients from the control group. In the study group, the INR ranged from 0.78–1.43 with a mean of 1.046 (SD=0.14), while in the control group the range was from 0.79–1.28, with a mean of 0.95 (SD=0.08). There was a significant difference in INR between the study and control groups (p<0.0001). Conclusions. The bite from V. berus does not result in severe thrombocytopenia, with only a moderate increase in INR values observed in about 7% of patients.
    Źródło:
    Annals of Agricultural and Environmental Medicine; 2018, 25, 4; 630-634
    1232-1966
    Pojawia się w:
    Annals of Agricultural and Environmental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Evaluation of antidote potential of methanol leaf extract of Bauhinia monandra on heparin-induced thrombocytopenia in mice
    Autorzy:
    Nworie, K.M.
    Okorie, A.N.
    Ebere, D.N.
    Obike, O.C.
    Powiązania:
    https://bibliotekanauki.pl/articles/79858.pdf
    Data publikacji:
    2019
    Wydawca:
    Polska Akademia Nauk. Czytelnia Czasopism PAN
    Tematy:
    thrombocytopenia
    methanol extract
    leaf extract
    Bauhinia monandra
    antidote potential
    phytochemical
    mice
    mouse
    Źródło:
    BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology; 2019, 100, 1
    0860-7796
    Pojawia się w:
    BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Cancer-related microagiopathic hemolytic anemia in a patient with breast cancer - diagnostic difficulties
    Autorzy:
    Skwierawska, Kamila
    Woźniak, Krzysztof
    Waszczuk-Gajda, Anna
    Drozd-Sokołowska, Joanna
    Kacprzyk, Piotr
    Chehab, Marita Rachid
    Boguradzki, Piotr
    Jędrzejczak, Wiesław Wiktor
    Basak, Grzegorz Władysław
    Powiązania:
    https://bibliotekanauki.pl/articles/2032969.pdf
    Data publikacji:
    2020-12-31
    Wydawca:
    Medical Education
    Tematy:
    cancer-related microangiopathic hemolytic anemia
    CR-MAHA
    breast cancer
    thrombotic microangiopathy
    thrombocytopenia
    Opis:
    Cancer-related microangiopathic hemolytic anemia is rarely recognized as a paraneoplastic syndrome with a very poor prognosis in cancer patients. The treatment and prognosis are significantly different from that in other thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. The case of described patient demonstrates the diagnostic difficulties in diagnosing the causes of hemolytic anemia in patient with breast cancer and appropriate treatment.
    Źródło:
    OncoReview; 2020, 10, 4; 134-138
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    A rare case of heparin-induced thrombocytopenia and cerebral venous sinus thrombosis with antiphospholipid syndrome and possible systemic lupus erythematosus
    Rzadki przypadek małopłytkowości wywoływanej przez heparynę i zakrzepicy zatok żylnych mózgu z zespołem antyfosfolipidowym i możliwym toczniem rumieniowatym układowym
    Autorzy:
    Stavropoulos, Ioannis
    Liverezas, Anastasios
    Papageorgiou, Eleni
    Tsiara, Sofia
    Powiązania:
    https://bibliotekanauki.pl/articles/1030008.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Communications
    Tematy:
    antiphospholipid syndrome
    cerebral venous sinus thrombosis
    heparin-induced thrombocytopenia
    intracerebral haemorrhage
    systemic lupus erythematosus
    Opis:
    Cerebral venous sinus thrombosis is a relatively rare type of stroke which can be complicated by intracerebral haemorrhage resulting often in poor prognosis. Antiphospholipid syndrome and systemic lupus erythematosus both have been associated with cerebral venous sinus thrombosis. Furthermore, a few cases combining heparin-induced thrombocytopenia with cerebral venous sinus thrombosis have been described in the literature. We present a 57-year-old female patient who was admitted reporting confusion and fever for 4 days. She was immobilized due to a thoracic vertebral fracture and received enoxaparin as a prophylaxis for deep venous thrombosis. A computed tomography scan demonstrated extensive cerebral venous sinus thrombosis and two ipsilateral haemorrhagic infarcts. Moreover, the patient was serum-positive for heparininduced thrombocytopenia antibodies and had persistent fever. A thorough immunological and serological investigation turned out consistent with antiphospholipid syndrome with possible systemic lupus erythematosus. The patient was treated accordingly and was finally discharged one month later, afebrile, with mild neurological deficits.
    Zakrzepica zatok żylnych mózgu jest względnie rzadkim typem udaru mózgu, który może być powikłany krwotokiem śródmózgowym i często wiąże się ze złym rokowaniem. Zespół antyfosfolipidowy i toczeń rumieniowaty układowy to znane czynniki ryzyka wystąpienia zakrzepicy zatok żylnych mózgu. Ponadto w  literaturze opisano kilka przypadków współwystępowania małopłytkowości wywoływanej przez heparynę z  zakrzepicą zatok żylnych mózgu. W  pracy przedstawiono przypadek 57-letniej kobiety przyjętej do szpitala z objawami splątania i gorączką trwającymi od 4 dni. Pacjentka była unieruchomiona z powodu złamania kręgu piersiowego kręgosłupa i przyjmowała enoksaparynę w ramach profilaktyki zakrzepicy żył głębokich. Tomografia komputerowa ujawniła rozległą zakrzepicę zatok żylnych mózgu i dwa obszary udaru krwotocznego zlokalizowane w tej samej półkuli mózgu. U pacjentki stwierdzono również pozytywny wynik badania w kierunku przeciwciał w surowicy odpowiedzialnych za wystąpienie małopłytkowości wywoływanej przez heparynę oraz uporczywą gorączkę. Dokładne badanie immunologiczne i serologiczne ujawniło obecność zespołu antyfosfolipidowego z możliwym toczniem rumieniowatym układowym. Pacjentka została poddana odpowiedniemu leczeniu i wypisana z oddziału miesiąc później, bez gorączki oraz z łagodnymi deficytami neurologicznymi.
    Źródło:
    Aktualności Neurologiczne; 2017, 17, 2; 121-125
    1641-9227
    2451-0696
    Pojawia się w:
    Aktualności Neurologiczne
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Zakrzepowa plamica małopłytkowa – diagnostyka i leczenie
    Thrombotic thrombocytopenic purpura – diagnosis and treatment
    Autorzy:
    Korsak, Jolanta
    Powiązania:
    https://bibliotekanauki.pl/articles/1032772.pdf
    Data publikacji:
    2013
    Wydawca:
    Medical Communications
    Tematy:
    ADAMTS13
    haemolytic uremic syndrome
    plasmapheresis
    thrombotic thrombocytopenia purpura
    zakrzepowa plamica małopłytkowa
    plazmafereza
    adamts13
    zespół hemolityczno-mocznicowy
    Opis:
    Thrombotic thrombocytopenic purpura (TTP) was once diagnosed with five manifestation: thrombocytopenia, microangiopathic haemolytic anaemia, nervous system malfunctioning, renal failure and fever. Yet 35% of patients in whom TTP is diagnosed do not develop all manifestations, i.e. neurologic manifestations, renal dysfunction and fever. At present the basis for TTP diagnosis is thrombocytopenia and microangiopathic haemolytic anaemia (MAHA). The diagnosis includes blood count, blood film, renal function, LDH level. A helpful parameter in diagnosing TTP is ADAMTS13 metalloproteinase and anti-ADAMTS13 antibodies. The treatment starts with therapeutic plasmapheresis. Plasmapheresis should be undertaken even when the diagnosis is not confirmed. It removes ULvWF multimers and acquired anti-ADAMTS13. Plasma transfusion is not as effective as plasmapheresis but it can be used provisionally. The effectiveness of the treatment is assessed by lack of thrombocytopenia normal LDH level, lack of anaemia and neurological disorders. Another therapeutic option is to use glicocorticosteroids and immunoglobulins. In some patients a beneficial procedure may be splenectomy. TTP therapy has recently employed rituximab. It reduces ADAMTS13 inhibitor ratio and increases proteinase activity. Rituximab treatment is reported to have resulted in clinical remissions in the cases where other treatment modalities failed.
    Zakrzepowa plamica małopłytkowa (thrombotic thrombocytopenic purpura, TTP) początkowo charakteryzowała się pentadą objawów: małopłytkowością, niedokrwistością hemolityczną mikroangiopatyczną, zaburzeniami układu nerwowego, niewydolnością nerek i gorączką. Jednak u 35% chorych z rozpoznaniem TTP nie stwierdza się wszystkich tych dolegliwości: nie występują u nich objawy neurologiczne, zaburzenia funkcji nerek oraz gorączka. Obecnie zakrzepową plamicę małopłytkową rozpoznaje się na podstawie małopłytkowości i niedokrwistości mikroangiopatycznej. Diagnostyka obejmuje badanie morfologiczne krwi obwodowej wraz z rozmazem, badanie czynności nerek i oznaczenie aktywności LDH. Pomocne w rozpoznaniu jest oznaczenie aktywności metaloproteazy ADAMTS13 i miana przeciwciał anty-ADAMTS13. W terapii w pierwszym rzucie stosuje się plazmaferezę leczniczą – powinna ona zostać przeprowadzona nawet wtedy, gdy diagnoza jest niepewna. Plazmafereza usuwa multimery ULvWF i nabyte przeciwciała skierowane przeciw ADAMTS13. Przetoczenie osocza nie jest tak efektywne jak plazmafereza, lecz może być stosowane tymczasowo. Efekt leczenia oceniany jest na podstawie unormowania się aktywności LDH oraz ustąpienia małopłytkowości, niedokrwistości i zmian neurologicznych. Inną możliwością terapeutyczną jest podawanie glikokortykosteroidów oraz immunoglobulin. U niektórych chorych korzystne może być wykonanie splenektomii. Ostatnio stosuje się także rytuksymab – powoduje on redukcję miana inhibitora ADAMTS13 i wzrost aktywności enzymu. Po leczeniu rytuksymabem odnotowano remisje kliniczne w przypadkach, w których zawiodły inne metody terapii.
    Źródło:
    Pediatria i Medycyna Rodzinna; 2013, 9, 4; 323-330
    1734-1531
    2451-0742
    Pojawia się w:
    Pediatria i Medycyna Rodzinna
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Zespół ciężkiej gorączki z trombocytopenią
    Severe fever with thrombocytopenia syndrome (SFTS)
    Autorzy:
    Gliński, Zdzisław
    Żmuda, Andrzej
    Powiązania:
    https://bibliotekanauki.pl/articles/22180777.pdf
    Data publikacji:
    2021
    Wydawca:
    Krajowa Izba Lekarsko-Weterynaryjna
    Tematy:
    psy
    koty
    epidemiologia
    wirus SFTS
    charakterystyka
    Haemaphysalis longicornis
    infekcja wirusowa
    objawy kliniczne
    przebieg choroby
    choroby człowieka
    choroby zwierząt
    zespół ciężkiej gorączki z trombocytopenią
    wektory wirusów
    severe fever with thrombocytopenia syndrome virus
    dogs
    cats
    humans
    Opis:
    Severe fever with thrombocytopenia syndrome (SFTS), is an emerging infectious zoonotic disease caused by a new phlebovirus, namely Huaiyangshan banyangvirus (family Phenuiviridae, Bunyavirales). The disease presents various clinical manifestations, including high fever, gastrointestinal signs, neurological signs, thrombocytopenia, leukocytopenia, lymphadenopathy and multiple organ failure, shown by elevated levels of serum alanine aminotransferase, aspartate aminotransferase, creatine kinase, and lactate dehydrogenase. SFTSV is transmitted by a bush tick, Haemaphysalis longicornis, bites and human-tohuman transmission has also been reported. SFTSV attacks primarily goats, cattle, dogs, cats, pigs, deer, elks, wild boars, chickens, rodents and shrews, small insectivorous mammals, but the clinical manifestations of SFTS have been reported mainly in dogs and cats. Dogs and cats, which live in close contact with their owners, serve as important mediators for transmitting virus to humans. Effective therapies or vaccines are not yet available. This review describes the different aspects of virology, pathogenesis, epidemiology and clinical symptoms of SFTS in animals and also in humans.
    Źródło:
    Życie Weterynaryjne; 2021, 96, 03; 173-176
    0137-6810
    Pojawia się w:
    Życie Weterynaryjne
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-14 z 14

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies